Case report
Open access
Sep 2026
Case Report: Trastuzumab deruxtecan combined with fulvestrant in a patient with HR+/HER2-low metastatic breast cancer
Breast cancer is the most common malignancy among women worldwide, and hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-low breast cancer poses significant challenges once resistance to endocrine therapy and CDK4/6 inhibitors develops. We present a 45-year-old female patient with HR+/HER2...
Jia-Ying Chai, Xin-Yi Zheng, Long-Yu Hu et al.
· Frontiers in Oncology · 0 citations